Aakash Babu has covered the pharmaceutical sector since 2018, starting his career at Reuters, where he specialised in tackling company news. Just before joining the Citeline team, he worked as a healthcare analyst at the Economist Group, focusing on disease trends, drug development, regulatory changes and pharmaceutical pricing. He has a master’s in economics and a post-graduate specialisation in business journalism from Asian College of Journalism-Bloomberg. He was a key member of the team that covered the initial breakthroughs in COVID-19 vaccine research during his time at Reuters. He also has experience in forecasting regulatory trends, drug approvals and pharmaceutical sales. Outside of work he enjoys traveling, writing and watching football.
Latest from Aakash Babu
The experimental GLP-1/amylin combination shows promise in type 2 diabetes, but competition will be fierce with some massive launches expected in 2026.
The pharma titan candidly speaks about the M&A landscape, high R&D costs and the potential of AI as the industry gets set to navigate a host of existing and new challenges.
The pharma titan candidly speaks about the M&A landscape, high R&D costs and the potential of AI as the industry gets set to navigate a host of existing and new challenges.
A Scrip analysis of cash positions, balance sheets and revenue at risk from patent loss and conference call commentary highlights M&A appetite among large pharma as well as mid-sized players.
The San Francisco, CA-based firm looks to keep its pipeline-in-a-product hopes alive for rezpeg with alopecia areata push.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years.